M. Pegram
Impact in
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Cancer Research top 10%
- Breast Cancer Treatment Studies
- Protease and Inhibitor Mechanisms
Papers in
- Oncology 13
- Cancer Treatment and Pharmacology 10
- HER2/EGFR in Cancer Research 8
- Colorectal Cancer Treatments and Studies 1
-
- Cancer, Hypoxia, and Metabolism 5
- Co-authors
- DJ Slamon (4 shared papers)Ravi Patel (1 shared paper)John Crown (1 shared paper)Tadeusz Pieńkowski (1 shared paper)David Reese (1 shared paper)D. Toppmeyer (1 shared paper)P. Fumoleau (1 shared paper)Mary-Ann Lindsay (1 shared paper)
- Journals
- Journal of Clinical Oncology (6 papers)JNCI Journal of the National Cancer Institute (2 papers)Annals of Oncology (1 paper)European Journal of Cancer Supplements (1 paper)PubMed (2 papers)
- Partner nations
- United StatesPolandSouth Korea
In The Last Decade
M. Pegram
14 papers receiving 548 citations
Peers
Comparison fields: 5 of 46
- Oncology 453
- Cancer Research 199
- Radiology, Nuclear Medicine and Imaging 182
- Immunology and Allergy 29
- Molecular Biology 177
Countries citing papers authored by M. Pegram
This map shows the geographic impact of M. Pegram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Pegram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Pegram more than expected).
Fields of papers citing papers by M. Pegram
This network shows the impact of papers produced by M. Pegram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Pegram. The network helps show where M. Pegram may publish in the future.
Co-authors
The 25 scholars most cited alongside M. Pegram, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 202 | |
| 2 | Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. | 2000 | 123 |
| 3 | 2004 | 110 | |
| 4 | Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. | 2001 | 58 |
| 5 | 2005 | 57 | |
| 6 | 2005 | 8 | |
| 7 | Current status and future directions of oral tyrosine kinase inhibitors in the treatment of cancer (part 3 of a 3-part series on angiogenesis inhibition in solid tumor malignancies). | 2006 | 3 |
| 8 | 2007 | 3 | |
| 9 | 2012 | 2 | |
| 10 | 2006 | 1 | |
| 11 | 2005 | 1 | |
| 12 | Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. | 2009 | 1 |
| 13 | 2008 | 1 | |
| 14 | 2011 | 1 |
About M. Pegram
M. Pegram is a scholar working on Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 14 papers that have together received 571 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (10 papers), HER2/EGFR in Cancer Research (8 papers), Cancer, Hypoxia, and Metabolism (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Neuroblastoma Research and Treatments (1 paper), Colorectal Cancer Treatments and Studies (1 paper), Angiogenesis and VEGF in Cancer (1 paper) and Lung Cancer Treatments and Mutations (1 paper). The work is most often cited by research in Oncology (453 citations), Cancer Research (199 citations), Radiology, Nuclear Medicine and Imaging (182 citations), Immunology and Allergy (29 citations) and Molecular Biology (177 citations). M. Pegram has collaborated with scholars based in United States, Poland and South Korea. Frequent co-authors include DJ Slamon, Ravi Patel, John Crown, Tadeusz Pieńkowski, David Reese, D. Toppmeyer, P. Fumoleau, Mary-Ann Lindsay, Michael Smylie and Michael F. Press. Their work appears in journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute, Annals of Oncology, European Journal of Cancer Supplements and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.